Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused
on generating data-driven insights to diagnose, understand and
treat rare diseases, and Insilico Medicine, an end-to-end
Artificial Intelligence (AI) -driven drug discovery company, today
announced a research and development collaboration to accelerate
the discovery of novel therapeutic targets for Niemann-Pick disease
type C. The duration of the research collaboration will initially
last 20 weeks.
As the framework for the collaboration, CENTOGENE will leverage
its Bio/Databank with multiomic patient data and NPC cell lines
(for transcriptomic data and validation of identified candidates),
through the use of Insilico’s comprehensive novel target discovery
AI platform for the identification of differential metabolites,
pathways, and genetic modifiers. Both Companies will analyze
identified targets before pursuing validation in CENTOGENE’s
cellular models, and CENTOGENE will retain exclusive rights to any
intellectual property generated by the research.
“I am thrilled by the collaboration between CENTOGENE and
Insilico. With the power of AI, we will accelerate the analysis and
knowledge discovery of multiomic data from patients affected with
NPC,” said Patrice Denèfle, Chief Scientific Officer at CENTOGENE.
“Using relevant human cellular models, we hope to crack the code
and validate meaningful and valuable insights on a disease for
which no cure has been found over the past decades using
traditional pharma approaches.”
“CENTOGENE’s rare disease-centric Bio/Databank is unique in the
richness of the data it holds. By leveraging Insilico’s powerful
proprietary AI platform, PandaOmics, with the multiomic research
data from CENTOGENE, I hope our collaboration will result in the
discovery of a therapeutic target for NPC,” said Alex Zhavoronkov,
Ph.D., Founder and CEO of Insilico Medicine. “Ultimately we want to
improve the quality of life for those affected by the
disease and bring tangible hope to thousands of NPC patients around
the world.”
If the research demonstrates translational robustness, a further
stage of drug development would become accessible – identifying
molecules that act on the identified targets. AI-based methods are
expected to accelerate this process – ultimately turning years into
months for both the target-to-hit and hit-to-lead phases.
“We are excited to be working together with Insilico as we seek
to identify novel therapeutic targets for NPC,” added Carsten
Ullrich, Ph.D., Senior Director of Artificial Intelligence at
CENTOGENE. “Combining both CENTOGENE’s expertise in multiomics and
unique global insights from the world’s largest NPC cohort with
Insilico’s next-generation AI platform has the potential to enable
an accelerated cure for this rare and often rapidly progressing
disease.”
To learn more about CENTOGENE’s AI Program, visit:
https://www.centogene.com/science/artificial-intelligence-initiative.html
This collaboration represents another significant step forward
for CENTOGENE’s mission to enable the cure of 100 rare diseases
within the next 10 years. To learn more, visit:
https://www.centogene.com/virtual-investor-event
About Niemann-Pick Disease Type C (NPC)
Niemann-Pick disease type C (NPC) is a genetic lipid storage
disease caused by mutations in the NPC1 and NPC2 genes that lead to
a heterogeneous spectrum of symptoms. This may include ataxia,
dystonia, vertical supranuclear gaze palsy, severe liver disease,
and interstitial lung disease, among others.
Onset may occur at varying ages, from neonatal to adulthood.
Life expectancy is reduced, and the estimated incidence is
approximately 1 in 120,000 births. It is important to note that
many cases go mis- or undiagnosed – creating difficulty around
determining the true frequency of NPC.
About Insilico Medicine
Insilico Medicine, an end-to-end artificial intelligence-driven
drug discovery company, is developing artificial intelligence
platforms. These platforms use deep generative models,
reinforcement learning, transformers, and other modern machine
learning techniques for novel target discovery and the generation
of novel molecular structures with desired properties. Insilico
Medicine is developing breakthrough solutions to discover and
develop innovative drugs for cancer, fibrosis, infectious diseases,
autoimmune diseases, and aging-related diseases. For more
information, please visit www.insilico.com.
About CENTOGENE
CENTOGENE engages in diagnosis and research around rare diseases
transforming real-world clinical, genetic, and multiomic data to
diagnose, understand, and treat rare diseases. Our goal is to bring
rationality to treatment decisions and to accelerate the
development of new orphan drugs by using our extensive rare disease
knowledge and data. CENTOGENE has developed a global proprietary
rare disease platform based on our real-world data repository of
over 600,000 patients representing over 120 different
countries.
The Company’s platform includes epidemiologic, phenotypic, and
genetic data that reflects a global population, as well as a
biobank of patients’ blood samples and cell cultures. CENTOGENE
believes this represents the only platform focused on comprehensive
analysis of multi-level data to improve the understanding of rare
hereditary diseases. It allows for better identification and
stratification of patients and their underlying diseases to enable
and accelerate discovery, development, and access to orphan drugs.
As of December 31, 2020, the Company collaborated with over 30
pharmaceutical partners.
Follow us on LinkedIn
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative worldwide economic conditions and ongoing instability and
volatility in the worldwide financial markets, the effects of the
COVID-19 pandemic on our business and results of operations,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth and enter into new
client relationships, our dependency on the rare disease industry,
our ability to manage international expansion, our reliance on key
personnel, our reliance on intellectual property protection,
fluctuations of our operating results due to the effect of exchange
rates, our ability to streamline cash usage, our requirement for
additional financing and our ability to continue as a going
concern, or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on April 15, 2021,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contact:
CENTOGENE
Ben Legg
Corporate Communications
Ben.Legg@centogene.com
Lennart Streibel
Investor Relations
Investor.Relations@centogene.com
Stern IR
Brendan Payne
+1 (212) 698 8695
brendan.payne@sternir.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2023 to Apr 2024